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Corynebacterium pseudotuberculosis (Cp) is a pathogenic bacterium that causes caseous lymphadenitis (CLA), ulcerative lymphangitis, 
mastitis, and edematous to a broad spectrum of hosts, including ruminants, thereby threatening economic and dairy industries worldwide. 
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began with the prediction of the modelome (tridimensional protein structures for the proteome of an organism, generated through 
comparative modeling) for 15 previously sequenced C. pseudotuberculosis strains. This pan-modelomics approach identified a set of 331 
conserved proteins having 95-100% intra-species sequence similarity. Next, we combined subtractive proteomics and modelomics to reveal 
a set of 10 Cp proteins, which may be essential for the bacteria. Of these, 4 proteins (tcsR, mtrA, nrdI, and ispH) were essential and non-host 
homologs (considering man, horse, cow and sheep as hosts) and satisfied all criteria of being putative targets. Additionally, we subjected 
these 4 proteins to virtual screening of a drug-like compound library. In all cases, molecules predicted to form favorable interactions and 
which showed high complementarity to the target were found among the top ranking compounds. The remaining 6 essential proteins (adk, 
gapA, glyA, fumC, gnd, and aspA) have homologs in the host proteomes. Their active site cavities were compared to the respective cavities 
in host proteins. We propose that some of these proteins can be selectively targeted using structure-based drug design approaches (SBDD). 
Our results facilitate the selection of C. pseudotuberculosis putative proteins for developing broad-spectrum novel drugs and vaccines. A 
few of the targets identified here have been validated in other microorganisms, suggesting that our modelome strategy is effective and can 
also be applicable to other pathogens. 
ESMHint 
Electronic supplementary material 
The online version of this article (doi:10.1186/1471-2164-15-S7-S3) contains supplementary material, which is available to authorized 
users. 
Background 
Antimicrobial resistance involving a rapid loss of effectiveness in antibiotic treatment and the increasing number of multi-resistant 
microbial strains pose global challenges and threats. Thereby, efforts to find new drug and/or vaccine targets to control them are becoming 
indispensible. Corynebacterium pseudotuberculosis (Cp) is a pathogen of great veterinary and economic importance, since it affects animal 
livestock, mainly sheep and goats, worldwide, and its presence is reported in other mammals in several Arabic, Asiatic, East and West African 
and North and South American countries, as well as in Australia [1]. C. pseudotuberculosis is a Gram-positive, facultative intracellular, and 
pleomorphic organism; it is non-motile, although presenting fimbriae [2]. Based on rpoB gene (a β subunit of RNA polymerase), it shows a 
close phylogenetic relationship with other type strains of CMNR (Corynebacterium, Mycobacterium, Nocardia and Rhodococcus), a group 
that comprises genera of great medical, veterinary and biotechnological importance [1, 3]. A recent study showed that phylogenetic analysis 
for the identification of Corynebacterium and other CMNR species based on rpoB gene sequences are more accurate than analyses based on 
16S rRNA [4]. Its pathogenicity and biological impact have already led to the sequencing of various strains of this pathogen from a wide range 
of hosts [3]. The pathogen causes several infectious diseases in goat and sheep population (biovar ovis), including caseous lymphadenitis 
(CLA), a chronic contagious disease characterized by abscess formation in superficial lymph nodes and in subcutaneous tissues. In severe 
cases, biovar equi infects the lungs, kidneys, liver and spleen, thereby threatening the herd life of the infected animals [2, 5]. The disease has 
been rarely reported in humans, as a result of occupational exposure, with symptoms similar to lymphadenitis abscesses [6–8]. The bacteria 
can survive for several weeks in soil in adverse conditions, what seems to contribute to its resistance and disease transmission [9, 10]. Direct 
contact to infectious secretions or contaminated materials are the primary sources of pathogen transmission between animals, but most 
frequently the infection occurs through exposed skin lacerations [5]. Given the medical importance of Cp and a lack of efficient medicines, in 
this study we applied a computational strategy to search for new molecular targets from this bacterium. 
Recently, computational approaches such as reverse vaccinology, differential genome analyses [11], subtractive and comparative microbial 
genomics have become popular for rapid identification of novel targets in the post genomic era [12], [13]. These approaches were used to 
identify targets in various human pathogens, like Mycobacterium tuberculosis [14], Helicobacter pylori [15], Burkholderia pseudomalleii [16],
Neisseria gonorrhea [17], Pseudomonas aeruginosa [18] and Salmonella typhi [19]. In general, such approaches follow the principle that 
genes/proteins must be essential to the pathogen and preferably have no homology to the host proteins [20]. Nevertheless, essential targets that 
are homologous to their corresponding host proteins may also be molecular targets for structure-based selective inhibitors development. In this 
case, the targets must show significant differences in the active sites or in other druggable pockets, when pathogenic and host proteins are 
compared [21–23]. 
Once a molecular target is chosen, the conventional experimental methods for drug discovery consist of testing many synthetic molecules or 
natural products to identify lead compounds. Such practices are laborious, time consuming and require high investments [24, 25]. On the other 
hand, computational methods for structure-based rational drug design can expedite the process of ligand identification and molecular 
understanding of interactions between receptor and ligand [26]. Such approaches are dependent on the availability of the structural information
about the target protein. Considering the availability of experimental structures in PDB (Protein Data Bank) only for a low percentage of the 
known protein sequences, comparative modeling is frequently the method of choice for obtaining 3D coordinates for proteins of interest [27] 
for the development of specific drugs and docking analyses [28, 29]. 
In this work, we used a modelomic approach for the predicted proteome of C. pseudotuberculosis species. This served to bridge the gap 
between raw genomic information and the identification of good therapeutic targets based on the three dimensional structures. The novelty of 
this strategy relies in using the structural information from high-throughput comparative modeling for large-scale proteomics data for inhibitor 
identification, potentially leading to the discovery of compounds able to prevent bacterial growth. The predicted proteomes of 15 C. 
pseudotuberculosis strains were modeled (pan-modelome) using the MHOLline workflow. Intra-species conserved proteome (core-modelome)
with adequate 3D models was further filtered for their essential nature for the bacteria, using the database of essential genes (DEG). This led to
the identification of 4 essential bacterial proteins without homologs in the host proteomes, which were employed in virtual screening of 
compound libraries. Furthermore, we investigated a set of 6 essential host homologs proteins. We observed residues of the predicted bacterial 
protein cavities that are completely different from the ones found in the homologous domains, and therefore could be specifically targeted. By 
applying this computational strategy we provide a final list of predicted putative targets in C. pseudotuberculosis, in biovar ovis and equi. 
They could provide an insight into designing of peptide vaccines, and identification of lead, natural and drug-like compounds that bind to these
proteins. 
Materials and methods 
_ _ _ _ ...
Genomes selection 
Proteomes predicted based on the genomes of fifteen C. pseudotuberculosis strains, including both biovar equi and biovar ovis (Table 1) 
were used in this study. Most of these genomes were sequenced by our group and are available at NCBI. We downloaded the genome 
sequences in gbk format from the NCBI server (ftp://ftp.ncbi.nih.gov/genomes/Bacteria) and the corresponding protein sequences (curated 
CDSs) were exported using Artemis Annotation Tool [30] for further analyses.  
Table 1  Strains of C. pseudotuberculosis employed in the pan-modelome study, and their respective information regarding genomes 
statistics, disease prevalence and broad-spectrum hosts. 
 
Pan-modelome construction 
A high throughput biological workflow, MHOLline (http://www.mholline.lncc.br), was used to predict the modelome (complete set of 
protein 3D models for the whole proteome) for each Cp strain. MHOLline uses the program MODELLER [31] for protein 3D structure 
prediction through comparative modeling. Furthermore, the workflow includes BLASTp (Basic Local Alignment Search Tool for Protein) 
[32], HMMTOP (Prediction of transmembrane helices and topology of proteins) [33], BATS (Blast Automatic Targeting for Structures), 
FILTERS, ECNGet (Get Enzyme Commission Number), MODELLER and PROCHECK [34] programs. The protocol used here was modified 
accordingly from the original work by Capriles et al., 2010 [35]. Briefly, the input files of protein sequences were used in FASTA format for 
all strains because the MHOLline accepts only .faa format files for the whole process. Firstly, MHOLline selected the template structures 
available at the Protein data Bank (PDB) via BLASTp (version 2.2.18), using the default parameters (e-value ≤ 10e-5). Secondly, the program 
BATS refined the BLASTp search for template sequence identification into different groups namely G0, G1, G2 and G3. Only the protein 
sequences in the group G2, which are characterized by an e-value ≤ 10e-5, Identity ≥ 0.25 and LVI ≤ 0.7 (where LVI is a length variation 
index of the BATS program for sequence coverage, the lower the LVI value, the higher the sequence coverage and vice versa) were selected. 
Among the MHOLline output files, the group G2 contained the largest number of protein sequences (≥ 50% for each input file). Subsequently, 
the "Filter" tool classified the group G2 sequences into seven distinct quality models groups, from "Very High" to "Very Low" depending on 
the quality of the template structure for a given query protein sequence. The program MODELLER then modeled all these groups in an 
automated manner. The number of sequences in the group G2 varies for each C. pseudotuberculosis strain. Only the first four distinct quality 
model groups of G2 were taken into consideration in this study, these were: 1- Very High quality model sequences (identity ≥ 75%) (LVI ≤ 
0.1), 2- High quality model sequences (identity ≥ 50%) and < 75%) (LVI ≤ 0.1), 3- Good quality model sequences (identity ≥ 50%) (LVI > 
0.1 and ≤ 0.3) and 4- Medium to Good quality models (identity ≥ 35% and < 50%) (LVI ≤ 0.3) (http://www.mholline.lncc.br). The percentage 
of identity represents identity between query and template sequences, a LVI ≤ 0.1 is equivalent to coverage of more than 90%, while LVI ≤ 
0.3 corresponds to coverage of more than 70%. Therefore, all protein 3D models considered in this study were built from sequences for which 
there existed a template with identity ≥ 35% and LVI coverage over 70%. Later on, the ECNGet tool assigned an Enzyme Commission (EC) 
number to each sequence in G2, according to the best PDB template. The MODELLER (v9v5) program performed the automated global 
alignment and 3D protein model construction. Finally, the program PROCHECK (v3.5.4) evaluated the constructed models based on their 
stereo-chemical quality. Additionally, transmembrane regions in the input protein sequences were predicted by HMMTOP, for putative 
vaccine and drug targets identification. 
Identification of intra-species conserved genes/proteins 
The words genes and proteins are interchangeably used here but they refer to the same protein target of the pathogen. For the identification 















Cp1/06-A 73235 NC_017308.1 2.28 1,963 52.2 Horse/USA Positive/equi Abscess Illumina 
Cp31 73223 NC_017730.1 2.3 2,063 52.2 Buffalo/Egypt Positive/equi Abscess Ion Torrent, 
SOLiD v3 
Cp258 157069 NC_017945.1 2.31 2,088 52.1 Horse/Belgium Positive/equi Ulcerative 
lymphangitis 
SOLiD v3 
Cp316 71591 NC_016932.1 2.31 2,106 52.1 Horse/USA Positive/equi Abscess Ion Torrent 
CpCIP52.97 61117 NC_017307.1 2.32 2,057 52.1 Horse/Kenya Positive/equi Ulcerative 
Lymphangitis 
SOLiD v2 
Cp162 89445 NC_018019.1 2.29 2,002 52.2 Camel/UK Positive/equi Neck Abscess SOLiD v3 
CpP54B96 77871 NC_017031.1 2.34 2,084 52.2 Antelope/S. 
Africa 
Negative/ovis CLA Abscess Ion Torrent, 
SOLiD v3 
Cp267 73515 NC_017462.1 2.34 2,148 52.2 Lhama/USA Negative/ovis CLA Abscess SOLiD v3 
Cp1002 40687 NC_017300.1 2.34 2,097 52.2 Goat/Brazil Negative/ovis CLA Abscess 454, Sanger 
Cp42/02-A 73233 NC_017306.1 2.34 2,051 52.2 Sheep/Australia Negative/ovis CLA Abscess Illumina 
CpC231 40875 NC_017301.1 2.33 2,095 52.2 Sheep/Australia Negative/ovis CLA Abscess 454, Sanger 
CpI19 52845 NC_017303.1 2.34 2,099 52.2 Bovine/Israel Negative/ovis Bovine Mastitis 
Abscess 
SOLiD v2 
Cp3/99-5 73231 NC_016781.1 2.34 2,142 52.2 Sheep/Scotland Negative/ovis CLA Illumina 
CpPAT10 61115 NC_017305.1 2.34 2,089 52.2 Sheep/Argentina Negative/ovis Lung Abscess SOLiD v2 
CpFRC41 48979 NC_014329.1 2.34 2,104 52.2 Human/France Negative/ovis Necrotizing 
lymphadenitis 
SOLiD v3 
of highly conserved proteins with 3D models in all Cp strains (≥ 95% sequence identity), the standalone release of NCBI BLASTp+ (v2.2.26) 
was acquired from the NCBI ftp site (ftp://ftp.ncbi.nlm.nih.gov/blast/executables/blast+/LATEST/), installed on a local machine and a search 
was performed for all strains using Cp1002 as a reference genome. The highly conserved proteins were selected using a comparative 
genomics/proteomics approach using an all-against-all BLASTp analysis with cut off values of E = 0.0001 [12 17 20 36]. 
Analyses of essential and non-host homologous (ENH) proteins 
To select conserved targets that were essential to the bacteria, a subtractive genomics approach was followed [20]. Briefly, the set of core-
modelome proteins from C. pseudotuberculosis were subjected to the Database of Essential Genes (DEG) for homology analyses. DEG 
contains experimentally validated essential genes from 20 bacteria [37]. The BLASTp cutoff values used were: E-value = 0.0001, bit score 
≥100, identity ≥ 35% [20]. 
Furthermore, the pool of essential genes was subjected to NCBI-BLASTp (E-value = 0.0001, bit score ≥100, identity ≥ 35%) against 
(human, equine, bovine and ovine proteomes) to identify essential non-host homologs targets [12]. The set of essential non-host homologous 
proteins were further crosschecked with the NCBI-BLASTp PDB database using default parameters to find any structural similarity with the 
available host homologs protein structures, keeping cutoff level to ≤ 15% for query coverage. These proteins were checked for their 
biochemical pathway using KEGG (Kyoto Encyclopedia of Genes and Genomes) [38], virulence using PAIDB (Pathogenicity island 
database) [39], functionality using UniProt (Universal Protein Resource) [40], and cellular localization using CELLO (subCELlular 
LOcalization predictor) [41]. The final list of targets was based on 12 criteria as described previously [20]. 
Analyses of essential and host homologous (EH) proteins 
We have extrapolated our analyses and also considered protein targets that were predicted as essential to bacterial survival but showed 
homology to host proteins. This was based on the possibility to find differences between bacterial and host proteins to rationally design 
inhibitors. The pool of essential protein targets that showed cut off values equal or higher than those for essential non-host homologs through 
NCBI-BLASTp was treated as host homologous proteins. These were also analyzed for pathway involvement, virulence, functional annotation 
and cellular localization like essential non-host homologous proteins. To verify the presence of significant residue differences in druggable 
protein cavities, a structural comparison was performed for each pathogen and their corresponding host protein through the molecular 
visualization program PyMOL (v1.5, Schrodinger, LLC) (http://www.pymol.org). The related published data of each template structure for 
each host homolog was also crosschecked for information about these residues, based on the PDB code of each template structure as input in 
the PDBelite server [42]. Catalytic Site Atlas (CSA) was also consulted to get robust information of the active site residues for the druggable 
enzyme targets [43]. CSA is a database documenting enzyme active sites and catalytic residues in enzymes of 3D structure and has 2 types of 
entry, original hand-annotated entries with literature references and homologous entries, found by PSI-BLAST alignment to an individual 
original entry, using an e-value cut-off of 0.00005. CSA can be accessed via a 4-letter PDB code. The equivalent residue that aligns in the 
query sequence to the catalytic residue found in the original entry is documented. Though the DoGSiteScorer predicts the druggable protein 
cavities, the host homologous proteins were further subjected to CASTp (Computed Atlas of Surface Topography of Proteins) [44], Pocket-
Finder and Q-SiteFinder [45] to get more reliable and robust results about the druggable cavities of the target proteins. 
Prediction of druggable pockets 
3D structure information and druggability analyses are important factors for prioritizing and validating putative pathogen targets [46, 47]. 
As aforementioned, for druggability analyses, the final list of essential non-host and host homologous protein targets in PDB format, were 
subjected to DoGSiteScorer [48], an automated pocket detection and analysis tool for calculating the druggability of protein cavities. For each 
cavity detected the program returns the residues present in the pocket and a druggable score ranging from 0 to 1. The closer to 1 the obtained 
values are, the more druggable the protein cavity is predicted to be, i.e. the cavities are predicted to be more likely to bind ligands with high 
affinity [48]. The DoGSiteScorer also calculates volume, surface area, lipophilic surface, depth and other related parameters for each 
predicted cavity. 
Virtual screening and docking analyses 
The ligand library was obtained from the ZINC database, containing 11,193 drug-like molecules, with Tanimoto cutoff level of 60% [49]. 
Proteins were inspected for structural errors such as missing atoms or erroneous bonds and protonation states in MVD (Molegro Virtual 
Docker) [50]. The cavities predicted with DogSiteScorer (druggability ≥ 0.80) for all protein targets, were compared with the cavities detected 
by MVD. The most druggable cavity, according to DogSiteScorer, was subjected to virtual screening. MVD includes three search algorithms 
for molecular docking namely MolDock Optimizer [50], MolDock Simplex Evolution (SE), and Iterated Simplex (IS). In this work the 
MolDock Optimizer search algorithm, which is based on a differential evolutionary algorithm, was employed. The default parameters used for 
the guided differential evolution algorithm are a) population size = 50, b) crossover rate = 0.9, and c) scaling factor = 0.5. The top ranked 200 
compounds for each protein were analyzed in Chimera for shape complementarity and hydrogen bond interactions, leading to the selection of 
a final set of 10 compounds for each target protein. 
Results and discussion 
Modelome and common targets in C. pseudotuberculosisspecies 
Here we report the identification of common putative targets among 15 strains of C. pseudotuberculosis species based on the construction 
of genome scale protein three-dimensional structural models. Structural information of target proteins can aid in drug and/or vaccine design 
and in the discovery of new lead compounds [51]. The approach employed here generated high-confidence structural models through the 
MHOLline workflow (Figure 1) from orthologous protein. To identify the common conserved proteins with a sequence similarity of 95-100%, 
a comparative genomics approach was performed where all the BATS classified G2 sequences from "Very High" to "Medium to Good" 
quality, from 14 Cp strains, were aligned to the G2 sequences of Cp1002, assumed as a reference genome for this study. In total, a set of 331 
protein sequences was selected, being conserved in all strains. An overview of the different steps involved in this computational approach for 





















































































































































































































































































































































































































































































Figure 2  Overview of different computational steps employed in the identification of putative essential targets (non-host 
homologous and host homologous) for drugs and vaccines from the core-proteome of 15 C . pseudotuberculosis strains. Figure 2b. 
Intra-species subtractive modelomics workflow for conserved targets identification in C. pseudo tuberculosis species. The table (from left to 
right) represents the total number of protein sequences as an input data in fasta format fed to the MHOLline workflow (upper forward 
arrow). The remaining columns show the output data of group G2 (upper backward arrow), first by BATS and then by Filter tools of the 
MHOLline workflow respectively. Columns 4th-7th constitute the number of protein sequences of different qualities of all 15 Cp strains, 
where the sequences of 14 Cp strains were compared using BLASTp, to the sequences of Cp1002 strain as reference, for the identification 
of conserved protein targets (core-modelome). The funnel shows how this workflow processes and filters a large quantity of genomic data 
for putative drug and vaccine targets identification of a pathogen. 
 
 
Identification of ENH and EH proteins as putative drug and/or vaccine 
targets 
To identify essential proteins as putative therapeutic targets in C. pseudotuberculosis, from the set of core-modelome, these were compared 
to the Database of Essential Genes (DEG). Based on this filter, the number of selected targets was reduced drastically to a final set of only 10 
targets. These were compared to the aforementioned corresponding host proteomes, leading to the identification of 4 essential non-host 
homologous proteins (ENH, Table 2) and 6 essential host homologous proteins (EH, Table 3).  

































1 2 25.97 MF: DNA binding, two-
component response 
regulator activity. BP: 
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1 4 36.59 MF: Metal ion binding, 4-
hydroxy-3-methylbut-2-en-
1-yl diphosphate reductase 



























aDruggability predicted with DoGSiteScorer software. A druggability score above 0.60 is considered to be good, but a score above 0.80 is 
favored [48]. 
bMolecular weight was determined using ProtParam tool (http://web.expasy.org/protparam/). 
cMolecular function (MF) and biological process (BP) for each target protein was determined using UniProt. 
dCellular localization of pathogen targets was performed using CELLO. 
eKEGG was used to find the role of these targets in different cellular pathways. 
fPAIDB was used to check if the putative targets are involved in pathogen's virulence. 
regulatory protein component response 
regulator activity, sequence-
specific DNA binding 
transcription factor activity








1 1 88.02 MF: ATP binding, 
ribonucleoside-diphosphate 
reductase activity, 
thioredoxin disulfide as 
acceptor 





Table 3  Drug and/or vaccine targets prioritization parameters and functional annotation of the six essential host homologous putative 
targets. 
 
aDruggability predicted with DoGSiteScorer software. A druggability score above 0.60 is usually considered, but a score above 0.80 is 
favored [48]. 
bMolecular weight was determined using ProtParam tool (http://web.expasy.org/protparam/). 
cMolecular function (MF) and biological process (BP) for each target protein was determined using UniProt. 
Gene and 
protein codes 































Cytoplasm Purine metabolism; AMP 










































Cytoplasm Carbohydrate metabolism; 
tricarboxylic acid cycle; 















Aspartate ammonia-lyase 2 4 52.277 MF: Lyase 
EC 4.3.1.1 




_ _ _ _
dCellular localization of pathogen targets was performed using CELLO. 
eKEGG was used to find the role of these targets in different cellular pathways. 
fPAIDB was used to check if the putative targets are involved in pathogen's virulence. 
Among the ENH proteins, two targets were selected from a bacterial unique pathway, the two component signaling system. These targets 
are tcsR (two-component response regulator) and mtrA (two component sensory transduction transcriptional regulatory protein). While the 
tcsR is a novel protein target, as it is has not been described so far as a target in any organism, mtrA has been already reported as a target in 
Mycobacterium [52] and provides multidrug resistance to Mycobacterium avium [53]. Therefore, targeting mtrA in C. pseudotuberculosis may 
also be effective in controlling the infection of CLA. The remaining ENH protein targets, nrdI and ispH, also participate in biochemical 
pathways. NrdI (ribonucleoside-diphosphate reductase alpha chain) is a flavodoxin which contains a diferric-tyrosyl radical cofactor and it is 
involved in nucleotide metabolism in E. coli [54]. It has been reported as a putative target in several pathogens including C. 
pseudotuberculosis, Corynebacterium diphtheriae and Mycobacterium tuberculosis [20]. The target ispH (4-hydroxy-3-methylbut-2-enyl 
diphosphate reductase; EC 1.17.1.2) is an essential cytoplasmic enzyme in Escherichia coli [55]. This iron-sulfur protein plays a crucial role in 
terpene metabolism of various pathogenic bacteria [56, 57] and it is a predicted target in Salmonella tyhpimurium [58] and Plasmodium 
falciparum [59]. It should be noted that according to the cut off threshold for NCBI-BLASTp that we have followed, ispH shows homology 
only to the human host. So, if human is not considered as a possible host, ispH can also be considered as a common putative target. The roles 
of these proteins in different metabolic pathways was confirmed from KEGG [38] and METACYC [60] databases. 
Prioritization parameters of drug and/or vaccine targets 
Previous studies have shown several factors that can aid in determining the suitability of therapeutic targets [46]. The availability of 3D 
structural information, the main approach of our study, is very helpful in drug development. Other important factors for drug targets include 
preferred low MW and high druggability. On the other hand, for vaccine targets the information about subcellular localization is important and 
proteins that contain transmembrane motifs are preferred [36, 46, 61, 62]. We have determined most of these prioritizing properties for the 10 
essential proteins (Table 2 &3). Interestingly, according to the target-prioritizing criterion, all targets have a low MW, and are predicted to be 
localized in the cytoplasmic compartment of the Cp. Druggability evaluation with DoGSiteScorer [48] for all conserved targets allowed the 
prediction of numerous druggable cavities with at least one druggable cavity for each Cp target. For the 4 ENH proteins tcsR, mtrA, nrdI, and 
ispH, 3, 5, 5 and 2 cavities with score ≥ 0.80 were observed respectively. For each protein, the cavity that exhibited the highest druggability 
score was selected for docking analyses. For 6 EH targets, adk, gapA, glyA, fumC, gnd, and aspA, 1, 3, 3, 2, 8 and 6 cavities were observed 
respectively according to the aforementioned druggability score criteria (Table 2 &3). Here, in each case, the most druggable predicted cavity 
was structurally compared with the cavities in respective host proteins. 
Virtual screening and molecular docking analyses of ENH targets 
For each ENH target protein (mtrA, ispH, tcsR and nrdl), the top 200 drug-like molecules from virtual screening were visually inspected to 
select 10 molecules that showed favorable interactions with the target. The biological importance of each target and an analysis of the 
predicted protein-ligand interaction are described below. ZINC codes and MolDock scores of selected ligands, the number of hydrogen bonds 
as well as protein residues involved in these interactions, are shown in a table for each target protein (Tables 4, 5, 6, 7. Figures showing the 
predicted binding mode for one of the 10 selected ligands are also shown for each target (Additional files 1, 2, 3, 4, 5).  
 
Table 4  ZINC codes, MolDock scores and predicted hydrogen bonds for the ten compounds selected among the top ranking 200 molecules 
against Cp1002_0515 (MtrA, DNA-binding response regulator). 
 
ZINC IDs MolDock score Number of H-bonds/ residues interacting with the compound 
75109074 -130.402 3 
Thr73, Asp48, Arg116 
12117405 -115.838 3 
Arg119, Arg118, Ala115 
02546720 -113.761 3 
Thr73, Arg119 
40266587 -116.119 2 
Asp48, Leu117 
71405274 -113.264 2 
Arg116, Asp97 
05687366 -111.376 2 
Arg119, Asp48 
04730243 -109.609 2 
Arg119, Asp157 
19720976 -109.061 2 
Arg119 
72342680 -108.299 2 
Arg119, Asp157 
against Cp1002_0742 (IspH, 4-hydroxy-3-methyl but-2-enyl diphosphate reductase). 
 
Table 6  ZINC codes, MolDock scores and predicted hydrogen bonds for the ten compounds selected among the top ranking 200 molecules 
against Cp1002_1648 (TcsR,Two component transcriptional regulator). 
 
 
Table 7  ZINC codes, MolDock scores and predicted hydrogen bonds for the ten compounds selected among the top ranking 200 molecules 
against Cp1002_1676 (NrdI). 
 
ZINC IDs MolDock score Number of H-bonds/ residues interacting with the compound 
00510419 -151.376 7 
Cys39, His68, Thr225, Ser250, Asn252 
00529019 -129.348 5 
His68, Ser250, Asn252, Thr193, Thr193 
04344036 -135.156 8 
Thr193, His151, His68, Ser251, Asn252, Ser250, Asn252 
04632419 -136.984 6 
Cys39, Gly41, Ala100, Cys222, Thr193, Asn252 
04730243 -129.414 10 
Cys222, Thr193, Asn252, His151, Ser250, His68, Ser250 
05479451 -129.963 9 
Asn252, Ser250, Ser251, His68, Cys123, Cys39, Gly41 
05775454 -161.806 3 
Asn252, Thr193, His68 
16941408 -126.163 6 
Thr193, Asn252, Asn252, Ser250 
04622741 -127.816 12 
Cys39, Cys123, His68, Cys222, Ser250, Ser251, His151, Thr193 
14017317 -129.664 8 
Cys39, Glu153, His68, Asn252, Ser251, Asn252, His151, Thr193 
ZINC IDs MolDock score Number of H-bonds/ residues interacting with the compound 
00510419 -167.633 3 
Val76, Gln185, Asn193 
01617096 -146.178 3 
Ala74, Gln185, Arg191 
32911447 -148.424 3 
Gln185, Ala70, Arg193 
00091802 -143.287 3 
Val76, Ala51 
67847806 -156.655 4 
Thr75, Thr75, Pro48, Val76 
19399766 -160.743 3 
Val76, Val76, Ala51 
16980834 -147.631 4 
Ala66, Val76 
06269029 -145.277 4 
Thr75, Pro48, Val76 
05934077 -145.785 3 
Arg191, Gln185 
01647971 -167.152 3 
Thr75, Val76, Ala51 
ZINC IDs MolDock score Number of H-bonds/ residues interacting with the compound 
01585114 -151.406 6 
Ser8, Ser7, Thr13, Asn12 
04721321 -144.134 7 
Ser8, Ser7, Thr13, Leu116 
17023683 -140.718 6 
Ser7, Ser8, Thr13, Thr13, Thr13 
00510419 -154.064 4 
Thr10, Thr13, Ser8 
01417445 -138.997 4 
Thr13, Tyr49, Ser8, Ser7 
 Table 5  ZINC codes, MolDock scores and predicted hydrogen bonds for the ten compounds selected among the top ranking 200 molecules 
Cp1002_0515 (MtrA, DNA-binding response regulator) is part of the two-component signal transduction system consisting of the sensor 
kinase (Histidine protein kinases, HKs) and the response regulator, MtrB and MtrA respectively. This system is highly conserved in 
Corynebacteria and Mycobacteria and it is essential for their survival to adapt to environmental changes. Homologs of MtrA and MtrB are 
present in many species of the genera Corynebacterium, Mycobacterium, Nocardia, Rhodococcus (CMNR), and others like 
Thermomonospora, Leifsonia, Streptomyces, Propionibacterium, and Bifidobacterium [63]. MtrA represents the fourth family member of the 
OmpR/PhoB family of response regulators. Like other family members, MtrA has been reported to be essential in M. tuberculosis [64]. It 
possesses an N-terminal regulatory domain and a C-terminal helix-turn-helix DNA-binding domain, already indicating that this response 
regulator functions as a transcriptional regulator, with phosphorylation of the regulatory domain modulating the activity of the protein [65]. 
Based on a comparison with a crystallographic structure of the MtrA template (2GWR, MtrA from M. tuberculosis), the active site residues 
involved in H-bond interactions with the crystallographic ligand are Val145, Gln151, Ile152 and Leu154. Although none of these residues is 
predicted to form hydrogen bonds with the ten selected docked ligands, these molecules were predicted to interact with other residues in the 
pocket. Table 4 shows the 10 selected ligands according to their minimum energy values and number of hydrogen bond interactions. 
ZINC75109074 (N-benzyl-N-[[2-(2-thienyl)-1H-imidazol-4-yl] methyl] prop-2-en-1-amine) is shown here as the top scoring ligand 
(Additional file 1). 
Cp1002_0742 (IspH, 4-hydroxy-3-methylbut-2-enyl diphosphate reductase) is an iron-sulfur oxidoreductase enzyme that plays a key role 
in the metabolism of terpenes in several pathogens. Terpenes constitute a large class of natural compounds. Their biosynthesis initiates with 
the building blocks isopentenyl-diphosphate (IPP) and dimethylallyldiphosphate (DMAPP), and differs in bacteria and mammals [57]. In 
bacteria and other pathogenic microorganisms the enzyme IspH catalyzes the last step in the production of IPP and DMAPP. The three 
structural units of the enzyme harbor a cubic iron-sulfur cluster at their center, enabling the enzyme to accomplish a challenging reaction by 
converting an allyl alcohol to two isoprene components. The iron-sulfur proteins normally participate in electron transfers. The IspH enzyme, 
thereby, in a similar fashion, binds the substrate directly to the iron-sulfur cluster [57]. In the template crystal structure of IspH (PDB 3KE8), it
has been shown that His41, His74, His124, Thr167, Ser225, Ser226, Asn227 and Ser269 are the active site residues that are involved in 
hydrogen bond interactions with the ligand 4-hydroxy-3-methylbutyldiphosphate (EIP). Also, Cys12, Cys96, Cys197 and EIP have been 
shown to make metal interaction with the Fe4S4 (Iron/Sulfur Cluster). Although the ten selected drug-like compounds (Table 5) did not show 
any interaction with the aforementioned IspH residues, they are predicted to make very good hydrogen bond interactions with other 
surrounding residues of the predicted cavity. The predicted binding mode of the best scoring compound, ZINC00510419 is shown in 
Additional file 2. Good shape complementarity and 6 hydrogen bond interactions are observed in this complex. 
Cp1002_1648 (TcsR, Two component transcriptional regulator) is a novel target without host homologs proteins. Differently from MtrA 
and IspH, in this case the template structure from Escherichia coli for TcsR did not contain any ligand (PDB 1A04), and no reported 
information was found about the ligand-residues interactions in their cavities. Therefore, among the cavities identified by MVD, the best 
cavity for virtual screening analysis was simply chosen based on the highest druggability score by the DogSiteScorer. Compound 
ZINC00510419 (Additional file 3) was the top-ranking compound, forming a network of 3 hydrogen bonds with Val76, Gln185 and Asn193. 
Table 6 lists the 10 compounds selected for this target. 
Cp1002_1676 (NrdI, protein) belongs to the nrdI protein family, a unique group of metalloenzymes that are essential for cell-proliferation 
[66]. It is classified as a ribonucleotide reductase (RNR), an iron-dependent enzyme that belongs to class Oxidoreductases (EC 1.17.4.1) acting
on CH or CH2 groups with a disulfide as acceptor [67]. The class Ia enzyme supplies deoxynucleotides during normal aerobic growth. The 
class Ib RNR plays a similar role although its function in E. coli is not clear, but it is reported to be expressed under oxidative stress and iron-
limited conditions [68]. Class I RNR enzymes have two homodimeric subunits, α2 (NrdE), where nucleotide reduction takes place, and β2 
(NrdF) containing an unidentified metallocofactor for initiating nucleotide reduction in α2. Although the exact function of NrdI within RNR 
has not yet been fully characterized, it is found in the same operon as NrdE and NrdF, and encodes an unusual flavodoxin, a bacterial electron-
transfer protein that includes a flavin mononucleotide that has been proposed to be involved in metallocofactor biosynthesis and/or 
maintenance. It has also been proposed that NrdI plays an important role in E. coli class Ib RNR cluster assembly. Recent in vitro studies have 
shown that a stable diferric-tyrosyl radical (FeIII2-Y·) and dimanganese (III)-Y· (MnIII2-Y·) cofactors are active in nucleotide reduction [69]. 
The first one can be formed by self-assembly from FeII and O2 while the later cofactor can be generated from MnII-2-NrdF, but only in the 
presence of O2 and NrdI protein [54, 69]. RNR is responsible for the de novo conversion of ribonucleoside diphosphates into 
deoxyribonucleoside diphosphates and it is essential for DNA synthesis and repair [70]. The active site residues of RNR, in the template 
structure of NrdI protein (PDB 3N3A), include Ser8, Ser9, Ser11, Ser48, Asn13, Asn83, Thr14, Tyr49, Ala89 and Gly91, all of which are 
involved in a hydrogen bond network with the cofactor flavin mononucleotide isoalloxazine ring (FMN, PDB 3N3A) [71]. Interestingly, two 
of these residues, Ser8 and Tyr49, were predicted to make hydrogen bonds with all 10 selected ligands (Table 7). The interaction between the 
top scoring compound ZINC01585114 (5-nitro-3, 4-diphenyl-2-furamide) and the residues from the predicted target cavities are shown in 
Additional file 4. 
Furthermore, the drug-like molecule ZINC00510419 (3,4-bis (5-methylisoxazole-3-carbonyl)-1,2,5-oxadiazole 2-oxide was among the top 
ten selected molecules for three of the pathogen target proteins, showing good H-bond interactions. It ranked first against the targets 
Cp1002_0742 (MolDock score = -151.376, no. of H-bonds = 7) and Cp1002_1648 (MolDock score = -167.633, no. of H-bonds = 3) and 
ranked fourth against the target Cp1002_1676 (MolDock score = -154.064, no. of H-bonds = 4). 
Essential host homologous as putative targets 
00042420 -135.363 6 
Tyr49, Ser7, Ser8, Thr13, Thr13, Thr13 
00408361 -133.535 6 
Thr13, Ser7, Ser8, Tyr49, Thr48 
15830653 -153.83 4 
Ser7, Thr13, Tyr49 
00032839 -139.327 6 
Ser8, Ser7, Thr13, Thr13, Thr13 
48212336 -137.675 6 
Ser7, Ser8, Ser8, Thr13, Ser54 
To compare the predicted EH protein targets to their host homologs, two approaches were taken. First, ClustalX (v2.1, 
http://www.clustal.org), a multiple sequence alignment program, was used to find different residues between bacterial and host proteins. As 
expected, a high percentage of residues was found to be conserved, but significant differences were also observed. Most percentage identities 
are between 35 and 50 (Table 8), except for fumarate hydratase, which shows 54% sequence identity to human and equine homologous 
proteins, but no hits in bovine and ovine proteomes.  
Table 8  Percentage of sequence identity between C. pseudotuberculosis and host homologous proteins. 
 
Next, to determine if the observed differences could be exploited in rational design of ligands selective to bacterial proteins, we focused on 
the predicted druggable cavities. A structural alignment to the host homologous proteins was performed and the cavities were compared in 
PyMol. In most cases, the DogSiteScorer predicted more than one cavity for each input Cp protein structure. The number of residues in the 
bacterial predicted cavity that differ from the residues in the cavity of the host protein, for all druggable pockets, varied from zero to seven 
(Table 9).  
Table 9  Comparison of the residues from druggable cavities in C. pseudotuberculosis proteins and the corresponding residues in 
structurally aligned host protein cavities. 
 
#Drug score ≥ 0.80 
*HS = Homo sapiens, EC = Equus caballus, BT = Bos taurus, OA = Ovis aries 
For conserved host-homologous targets Cp1002_0385 (adk, Adenylate kinase), Cp1002_0692 (gapA, Glyceraldehyde 3-phosphate 
dehydrogenase), Cp1002_0728 (glyA, Serine hydroxymethyltransferase), Cp1002_0738 (fumC, Fumarate hydratase class II/fumarase), 
Cp1002_1005 (gnd, 6-Phosphogluconate dehydrogenase) and Cp1002_1042 (aspA, Aspartate ammonia-lyase/aspartase), three, four, five, 
Protein Locus tag Official full name Percentage of Sequence Identity# 
  HS* EC* BT* OA* 
Cp1002_0385 Adk Adenylate kinase 38 36 35 35 
Cp1002_0692 GapA Glyceraldehyde-3-phosphate dehydrogenase A 39 40 41 41 
Cp1002_0728 GlyA Serine hydroxymethyltransferase 43 45 45 45 
Cp1002_0738 FumC Fumaratehydratase class II 54 54 No Hits No Hits 
Cp1002_1005 Gnd 6-phosphogluconate dehydrogenase 48 48 48 48 
Cp1002_1042 AspA Aspartate ammonia-lyase 39 39 39 39 
Protein Loci Bacterial Residues for the Most Druggable Cavity Predicted 
by DGSS Server# 




Lys157 Asp35 Asp33 Asp33 Asp33
 Val174 Thr52 Thr50 Thr50 Thr50
 Arg229 Thr103 Thr101 Thr101 Thr101
 Asn311 Ala183 Ala181 Ala181 Ala181
Cp1002_0385 
(Adenylate kinase) 
Phe35 Leu50 Leu52 Leu52 Leu43
 Ile53 Met68 Met70 Met70 Met61
 Thr64 Val79 Val81 Val81 Val72
Cp1002_0728 
(Serine hydroxymethyltransferase) 
Cys70 Ala88 Thr86 Thr86 Thr86
 Ala99 Ser121 Ser119 Ser119 Ser119
 Ala101 Ser123 Ser121 Ser121 Ser121
 Trp177 Thr204 Thr202 Thr202 Thr202
 Pro361 Ala397 Ala395 Ala395 Ala395
Cp1002_1005 
(6-phosphogluconate dehydrogenase) 
Ser55 Thr35 Thr161 Thr35 Thr35
 Met94 Leu74 Leu200 Leu74 Leu74
 Gln96 Lys76 Lys202 Lys76 Lys76
 Val104 Phe84 Phe210 Phe84 Phe84
 Ile148 Val128 Val254 Val128 Val128
 Gln268 Lys248 Lys374 Lys248 Lys248
 Pro269 His249 Tyr375 His249 His249
Cp1002_1042 
(Aspartate ammonia-lyase) 
Gln193 His235 His257 His235 His235
 Ile428 Lys470 Lys492 Lys470 Lys470
 His447 Leu489 Leu511 Leu489 Leu489
zero, seven and three different residues were observed, respectively. Then, a more detailed analysis was performed for the predicted highest 
druggable cavity for each protein. The results are described below, together with information about the biological importance of each target 
protein. 
Cp1002_0692 (GapA, Glyceraldehyde 3-phosphate dehydrogenase, GAPDH/G3PDH, EC 1.2.1.12) catalyzes the sixth step of glycolysis. 
In addition, GAPDH has recently been shown to be involved in several non-metabolic processes, including transcription activation, initiation 
of apoptosis [72] fast axonal or axoplasmic transport and endoplasmic reticulum to Golgi vesicle shuttling [73, 74]. This enzyme has been 
reported as an anti-trypanosomatid and anti-leishmania drug target in structure-based drug design efforts [21–23]. Furthermore, it has been 
shown as an interesting putative drug and vaccine target in malaria pathogenesis [75]. Comparison of protein cavities reveals significant 
differences between bacterial and host proteins, with replacement of bacterial Lys157, Arg229 and Asn311 by Asp, Thr and Ala, respectively. 
Such differences result in a more basic cavity in bacteria, making it possible to rationally design selective ligands, especially negatively 
charged molecules, which interact with Lys157 and Arg229, or compounds able to form hydrogen bond to Asn311 (Additional file 5a). 
Nucleoside monophosphate kinases vitally participate in sustaining the intracellular nucleotide pools in all living organisms. Cp1002_0385 
(Adk, Adenylate kinase, EC 2.7.4.3) is a ubiquitous enzyme, which catalyzes the reversible Mg2+-dependent transfer of the terminal 
phosphate group from ATP to AMP, releasing two molecules of ADP [76]. Only one highly druggable cavity was predicted for adenylate 
kinase, with a druggability score = 0.81. Three residues in the bacteria cavity were different from the hosts: Leu, Met and Val in the hosts 
replaced Phe35, Ile53 and Thr64, respectively (Additional file 5b). These differences impact the cavity volume, since aromatic and bulky Phe 
is replaced by Leu, and the ability to make hydrogen bonds, through the replacement of a Thr by a Val. Therefore; the bacterial cavity is 
smaller and more hydrophilic, making it possible to envision rational design of selective ligands that interact with Thr64. 
Cp1002_0728 (GlyA, Serine hydroxymethyltransferase EC 2.1.2.1) is an enzyme that plays an important role in cellular one-carbon 
pathways by catalyzing the reversible, simultaneous conversions of L-serine to glycine (retro-aldol cleavage) and tetrahydrofolate to 5,10-
methylenetetrahydrofolate [77]. In Plasmodium, serine hydroxymethyltransferase (SHMT) has been reported as an attractive drug target [78]. 
For this protein 3 residues were observed different between bacteria and host: Ala99 and Ala101 replaced two Ser residues while Trp177 
replaced Thr (Additional file 5c). At first glance these changes could have a big impact in the active site, generating a considerably more 
hydrophilic pocket in the hosts. However, careful inspection of the pocket reveals that the side chains of these residues are not turned towards 
the pocket, in such a way that these differences probably would not allow rational design of selective ligands. 
Cp1002_0738 (FumC, Fumaratehydratase class II/fumarase EC 4.2.1.2) catalyzes the reversible hydration/dehydration of fumarate to S-
malate during the ubiquitous Krebs cycle, through the aci-carboxylate intermediate subsequent to olefin production [79]. There are two classes 
of fumarases; Class I fumarases, composed of heat-labile, iron-sulfur (4Fe-4S) homodimeric enzymes, only found in prokaryotes; and Class II 
fumarases, made of thermostable homotetrameric enzymes [80] found in both prokaryotic and eukaryotic mitochondria. Class II belongs to a 
superfamily that also includes aspartate-ammonia lyases, arginino-succinatases, d-crystallins and 3-carboxy-cis, cis-muconate lactonizing 
enzymes. All these enzymes release fumarate from different substrates, ranging from adenylosuccinate to malate [81–84]. FumC of 
Escherichia coli is the first member of class II fumarases family whose structure has been solved and provided most of the structural 
information [85]. Inhibition of fumarase in the tricarboxylic acid cycle (TCA) has been reported as a potential molecular target of bismuth 
drugs in Helicobacter pylori [86]. Comparison of the active site cavity of this protein, which is formed in the interface of three monomers, 
revealed no differences between bacteria and hosts (additional file 5d). 
Cp1002_1005 (Gnd, 6-Phosphogluconate dehydrogenase EC 1.1.1.44) is an enzyme from the pentose phosphate pathway. It forms ribulose 
5-phosphate from 6-phosphogluconate. The enzyme 6-phosphogluconate dehydrogenase is a potential drug target for the parasitic protozoan 
Trypanosoma brucei, the causative organism of human African trypanosomiasis [87]. Three druggable sites with score > 0.80 were detected in 
this protein. As opposed to the observation for other proteins, the most druggable predicted cavity (score = 0.88) was not the active site. Leu, 
Lys and Val residues in the hosts replace residues Met94, Gln96 and Ile148 in the bacterial cavity, respectively (Additional file 5e). The most 
significant of these differences is the replacement of Gln by Lys, which could make binding of negative molecules more favorable to the host 
proteins. 
Cp1002_1042 (AspA, Aspartate ammonia-lyase/aspartase EC 4.3.1.1) catalyzes the deamination of aspartic acid to form fumarate and 
ammonia [88]. Recent progresses to prepare enantiopure l-aspartic acid derivatives, highly valuable tools for biological research and chiral 
building blocks for pharmaceuticals and food additives, make it a target of interest for industrial applications. On the other hand, the important 
role that it plays in microbial nitrogen metabolism makes it a putative drug target in overcoming bacterial pathogenesis [89]. Based on the 
sequence alignment for this protein, two significant differences in residues are observed in the most druggable pocket: bacterial His447 and 
Ile428 are replaced by Leu and Lys in host proteins. Such differences should allow rational ligand design. It is interesting to note that 
additional differences in the position of helices that contain these residues increase the difference between the active sites (Additional file 5f). 
Based on the above-mentioned analyses, we conclude that it would be difficult to rationally design selective ligands for Cp1002_0738 
(FumC, Fumaratehydratase class II), since no residue differences were observed in the most druggable cavity, and for Cp1002_0728 (GlyA, 
Serine hydroxymethyltransferase), where the side chains of differing residues are not turned toward the druggable pocket. On the other hand, 
for putative essential and homologous targets that include Cp1002_0692 (GapA, Glyceraldehyde 3-phosphate dehydrogenase), Cp1002_0385
(Adk, Adenylate kinase), Cp1002_1005 (Gnd, 6-Phosphogluconate dehydrogenase) and Cp1002_1042 (AspA, Aspartate ammonia-lyase), 
significant differences were observed in druggable pockets, suggesting that despite the existence of a host homologous protein they could be 
good targets for the design of ligands, selective only to the bacterial proteins. 
Conclusion 
Here, for the first time, the genomic information was used to determine the conserved predicted proteome of 15 strains of C. 
pseudotuberculosis, along with their three-dimensional structural information. Even though the structural information discussed is fully 
computationally predicted, and could therefore deviate from eventually solved experimental structures, we have been careful to concentrate on 
the analysis of protein models for which there were good templates which provided high quality models, minimizing this concern. The data 
presented here can effectively contribute in guiding further research for antibiotics and vaccines development. The final dataset can provide 
valuable information in designing molecular biology and immunization experiments in animal models for validating the targets of a pathogen, 
as well as in experimental structure determination protocols. 
targets, of which four are essential and non-homologous and six are essential and host homologous proteins. For the latter, a detailed structural 
comparison between the residues of the predicted cavities of host and pathogen proteins has been performed, showing in most cases the 
potential for the development of selective ligands. Therefore, we suggest that the whole set can be considered for antimicrobial chemotherapy, 
especially the four essential non-host homologous targets. 
The in silico approaches followed in this study might aid in the development of novel therapeutic drugs and vaccines in a broad-spectrum of 
hosts at intraspecies level against C. pseudotuberculosis. Furthermore, the strategy described here could also be applied to other pathogenic 
microorganisms. 
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Additional file 1: Docking representation of the best drug-like compound ZINC75109074 in the most druggable protein cavity of 
Cp1002_0515 (MtrA, DNA-binding response regulator). Three hydrogen bonds were observed with Thr73, Asp48 and Arg116. (PDF 1 MB) 
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Additional file 2: Docking representation of compound ZINC00510419 in the most druggable protein cavity of Cp1002_0742 (IspH, 4-
hydroxy-3-methyl but-2-enyl diphosphate reductase). Residues Cys39, Thr225, Ser250, His68 and Asn252 are predicted to make seven 
hydrogen bonds to this ligand. (PDF 932 KB) 
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Additional file 3: Docking representation of the best drug-like compound ZINC00510419 in the most druggable protein cavity of 
Cp1002_1648 (TcsR, Two component transcriptional regulator). Hydrogen bonds were observed with residues Val76, Gln185 and Asn193. 
(PDF 1 MB) 
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Additional file 4: Docking representation of the best drug-like compound ZINC04721321 in the most druggable protein cavity of 
Cp1002_1676 (NrdI protein). Hydrogen bonds were observed with residues Ser8, Thr13 and Leu116. (PDF 1 MB) 
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Additional file 5 (a-f): Comparison among the most druggable cavities from essential bacterial and the respective host homologue proteins. 
Protein structures are shown as cartoon (green for the bacterial protein and gray for Ovis aries host protein). Other host proteins are not shown 
for simplicity, but the same substitutions were present in all host proteins analyzed. Residues that differ in the bacterial and host cavity are 
highlighted in sticks and labeled (bacterial labels in green and host labels in black). a) Cp1002_0692 (Glyceralderayde 3-phosphate 
dehydrogenase); b) Cp1002_0385 (adenylate kinase); c) Cp1002_0728 (serine hydroxymethyltransferase); d) Cp1002_0738 (fumarate 
hydratase class II) the site shown is formed by three monomers, which are represented in green, blue and orange. No residues are highlighted, 
since the active sites are identical between bacteria and host; e) Cp1002_1005 (6-phosphogluconate dehydrogenase); f) Cp1002_1042 
(aspartate ammonia-lyase). Figures were prepared with the PyMol. (PDF 4 MB) 
The criterion for target selection in C. pseudotuberculosis was stringent, resulting in a small set of prioritized putative drug and vaccine 
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